Telix at EANM 2024

Telix’s extensive theranostic pipeline will be showcased in a sponsored symposium and presentations covering: TLX250-CDx  (Zircaix®, 89Zr-girentuximab) kidney cancer imaging, including first real-world clinical experience; TLX101 (131I-iodofalan or 131I-IPA) glioblastoma therapy; TLX66 (90Y-besilesomab) bone marrow conditioning therapy; TLX252 (225Ac-girentuximab) carbonic anhydrase IX (CAIX)-targeted alpha therapy; and SENSEI®, Lightpoint’s robotic-assisted gamma probe. 

19 – 23 October 2024
Hamburg, Germany
Presentations
Professor Viktor Grünwald

University Hospital Essen, Essen, Germany.

Chairperson
Prof. Arturo Chiti

IRCCS San Raffaele Hospital, Milan, Italy 

Why size matters: The relative benefits of antibodies vs. small molecules in oncology
Prof. Nathalie Albert

Ludwig-Maximilian’s-University of Munich, Munich, Germany 

When small may be smart: The role of small molecules in neuro-oncology
Prof. Stefano Fanti

University of Bologna, Bologna, Italy

Where big may be best: The power of antibodies in onco-hematology
Prof. Karolien Goffin

University Hospital Leuven, Leuven, Belgium

How size will shape the future: The choice between antibodies and small molecules in uro-oncology

Does size matter in targeted radionuclide therapies?

A Telix Sponsored Symposium

Sunday, 20 October, 2024 | 13:15 – 14:45 CEST 
Hall G1, Congress Center Hamburg

Abstract presentations 

Unravelling radiobiological and immunological mechanisms driving effective CAIX-TRT and ICI combination therapy
S. Kleinendorst, RadboudUMC, Netherlands
Accuracy of personalised single time point dosimetry for bone marrow and liver dosimetry in TLX66 (90Y-Anti CD66) radioimmunotherapy
A. Nautiyal, University Hospital Southampton, United Kingdom
Tumour margin thickness inference for 99mTc radio-guided surgery using internal conversion electrons
J. Moo, Telix
Radiation protection considerations with TLX250-CDx (89Zr-girentuximab) PET/CT experience in France
C. Morgat, Department of Nuclear Medicine, University Hospital of Bordeaux, France
Correlation of tracer uptake in sentinel lymph nodes as measured on SPECT/CT and during intraoperative gamma tracing with the SENSEI drop in gamma probe: the UZ Leuven experience
M. Manley, Nuclear Medicine, University Hospitals Leuven, Belgium
Development of 161Tb-DOTA-HYNIC-panPSMA for targeted radionuclide therapy of prostate Cancer
C. Morgat, Department of Nuclear Medicine, University Hospital of Bordeaux, France
Feasibility and tolerability of TLX101 (131I-IPA) monotherapy in progressive and recurrent high grade gliomas; an ongoing single institution case series
N. Tolboom, University Medical Centre Utrecht, Netherlands
The emerging role of TLX250-CDx (89Zr-girentuximab) PET/CT in accurate characterisation and staging of ccRCC: early experience with three patients
F. Gelardi, Università Vita-Salute San Raffaele, Italy
Development of girentuximab as a theranostic tool in non-renal indications
A. Ivashkevich, Telix
Preclinical evaluation of DNA damage response inhibitors and TLX252 (225Ac-DOTA-girentuximab) combination therapy
Z. Cao, Olivia Newton-John Cancer Research Institute, Australia
Poster Presentations
e-Poster Area
Unravelling radiobiological and immunological mechanisms driving effective CAIX-TRT and ICI combination therapy
S. Kleinendorst, RadboudUMC, Netherlands

Date and Time: 20-Oct-24, 08:00 – 09:30 

Session
Cutting Edge Science Track – TROP Session: Dosimetry Committee: Preclinic and Radiobiology
Format: Oral

Location: Hall Y4-Y9 

Presentation ID: OP-022 

Accuracy of personalised single time point dosimetry for bone marrow and liver dosimetry in TLX66 (90Y-Anti CD66) radioimmunotherapy
A. Nautiyal, University Hospital Southampton, United Kingdom

Date and Time: 20-Oct-24, 15:00 – 16:30 

Session
Session: Cutting Edge Science Track – TROP Session: Dosimetry Committee: Dosimetry: A Question of Time
Format: Oral

Location: Hall Y4-Y9 

Presentation ID: OP-158 

Tumour margin thickness inference for 99mTc radio-guided surgery using internal conversion electrons
J. Moo, Telix

Date and Time: 21-Oct-24, 08:00 – 09:30 

Session
Cutting Edge Science Track – TROP Session: Physics Committee: Data Corrections / Image Enhancement
Format: Oral

Location: Hall Y4-Y9 

Presentation ID: OP-289 

Radiation protection considerations with TLX250-CDx (89Zr-girentuximab) PET/CT experience in France
C. Morgat, Department of Nuclear Medicine, University Hospital of Bordeaux, France

Date and Time: 21-Oct-24, 15:00 – 16:30

Session
TROP Session: Radiation Protection Committee: Radiation Protection in Diagnostic Imaging Procedures
Format: Oral

Location: Hall Y1-Y3 

Presentation ID: OP-452 

Correlation of tracer uptake in sentinel lymph nodes as measured on SPECT/CT and during intraoperative gamma tracing with the SENSEI drop in gamma probe: the UZ Leuven experience
M. Manley, Nuclear Medicine, University Hospitals Leuven, Belgium

Date and Time: 22-Oct-24, 08:00 – 09:30 

Session
Cutting Edge Science Track – TROP Session: Physics Committee: SPECT/CT Quantification
Format: Oral

Location: Hall Y4-Y9 

Presentation ID: OP-543 

Development of 161Tb-DOTA-HYNIC-panPSMA for targeted radionuclide therapy of prostate Cancer
C. Morgat, Department of Nuclear Medicine, University Hospital of Bordeaux, France

Date and Time: 22-Oct-24, 08:00 – 09:30 

Session
M2M Track – TROP Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: From Radionuclide to Clinical Translation
Format: Oral

Location: Hall X1-X4 

Presentation ID: OP-532 

Feasibility and tolerability of TLX101 (131I-IPA) monotherapy in progressive and recurrent high grade gliomas; an ongoing single institution case series
N. Tolboom, University Medical Centre Utrecht, Netherlands

Date and Time: 22-Oct-24, 16:45 – 18:15 

Session
TROP Session: Neuroimaging Committee: Neuro-Oncology
Format: Oral

Location: Hall Y10-Y12 

Presentation ID: OP-758 

The emerging role of TLX250-CDx (89Zr-girentuximab) PET/CT in accurate characterisation and staging of ccRCC: early experience with three patients
F. Gelardi, Università Vita-Salute San Raffaele, Italy

Date and Time: 23-Oct-24, 08:00 – 09:30

Session
TROP Session: Case Report Session 2: You Won’t Believe the Things I’ve Seen!
Format: Oral

Location: Hall Y1-Y3 

Presentation ID: OP-824 

Development of girentuximab as a theranostic tool in non-renal indications
A. Ivashkevich, Telix

Date and Time: 23-Oct-24, 08:00 – 09:30

Session
e-Poster Presentations Session 13: Translational Molecular Imaging & Therapy Committee: Molecular Imaging & Therapy
Format: Oral ePoster

Location: Hall F 

Presentation ID: EPS-270 

Preclinical evaluation of DNA damage response inhibitors and TLX252 (225Ac-DOTA-girentuximab) combination therapy
Z. Cao, Olivia Newton-John Cancer Research Institute, Australia

Date and Time: 23-Oct-24, 08:00 – 09:30 

Session
e-Poster Presentations Session 13: Translational Molecular Imaging & Therapy Committee: Molecular Imaging & Therapy
Format: Oral ePoster

Location: Hall F 

Presentation ID: EPS-269 

Poster Presentations
e-Poster Area
Presentations
Development of Kit-Composition for the Preparation of 99mTc-PSMA-GCK01 / RHN001-Dx
J. Cardinale
University Hospital Duesseldorf, Germany

Session: D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control 

Format: e-Poster 

Location: e-Poster Area 

Presentation ID: EP-1037 

Development of 18F-labelled lactate for oxidative cancer imaging
M. da Silva Morais
Pole of Pharmacology, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Belgium

Session: D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D55 Radiopharmacokinetics and Drug Development  

Format: e-Poster 

Location: e-Poster Area 

Presentation ID: EP-1010 

Radiolabelling DOTA-HYNIC-panPSMA with actinium-225 for in vivo studies
K. Attia
Telix

Session: D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D53 New Radiopharmaceuticals – Therapy 

Format: e-Poster 

Location: e-Poster Area 

Presentation ID: EP-0985